Roche Faces Setback: India Supreme Court Permits Generic Sales of Rare Disease Drug
- The ruling prioritizes patient access over pharmaceutical profits, paving the way for a considerably cheaper option to Evrysdi, a treatment for spinal muscular atrophy.
- In a landmark decision, India's Supreme Court dismissed Roche's petition seeking to prevent Natco Pharma from selling a generic version of Evrysdi.
- The core of the dispute centered on the high cost of Evrysdi, a medication used to treat Spinal Muscular Atrophy (SMA), a devastating genetic disorder.
“`html
India’s Supreme Court Allows Generic Version of Roche’s Rare Disease Drug
Table of Contents
The ruling prioritizes patient access over pharmaceutical profits, paving the way for a considerably cheaper option to Evrysdi, a treatment for spinal muscular atrophy.
The Ruling: Profits vs.patients
In a landmark decision, India’s Supreme Court dismissed Roche’s petition seeking to prevent Natco Pharma from selling a generic version of Evrysdi. This ruling follows an earlier decision this month by a lower court that affirmed allowing Natco to sell the drug would serve the public interest.
The core of the dispute centered on the high cost of Evrysdi, a medication used to treat Spinal Muscular Atrophy (SMA), a devastating genetic disorder. Roche charges approximately $6,982 per bottle, while natco’s proposed generic version is priced around $179 – a difference of over 3,800%.
Understanding Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy is a rare genetic disease characterized by the loss of motor neurons, leading to muscle weakness and atrophy. The severity of SMA varies, but the most severe form (Type 1) can be fatal by age two if left untreated. It’s caused by a deficiency in the SMN protein, crucial for motor neuron survival.
While genetic testing can identify carriers, early diagnosis is frequently enough challenging. Newborn screening for SMA is becoming increasingly common in developed countries, but remains limited in many regions, including parts of india.
Key SMA Facts:
- Prevalence: Approximately 1 in 10,000 births globally.
- Genetic Cause: Mutation in the SMN1 gene.
- Treatment Options: Evrysdi (risdiplam), Spinraza (nusinersen), and Zolgensma (onasemnogene abeparvovec-xioi) are currently approved therapies.
The Access Gap in India
Despite a population of over 1.4 billion, access to life-saving SMA treatments in India has been severely limited by cost. Advocacy groups estimate that over 5,000 people in India live with SMA, and approximately 3,200 children are born with the condition each year. However, as of last year, fewer than 170 patients had access to Evrysdi.
The annual cost of treatment for an adult patient is approximately $81,000. While Roche offers a patient assistance program, the Delhi High Court recently described its reach as “minuscule,” leaving the vast majority of patients unable to afford the medication.
| Treatment | Approximate Annual Cost (USD) |
|---|---|
| Evrysdi (Roche) | $81,000 |
| Natco Pharma Generic | $10,752 (based on $179/bottle x 60 bottles/year) |
| Spinraza (Biogen) | $750,000+ (lifetime) |
| Zolgensma (Novartis) | $2.125 million (one-time) |
Legal Background and Compulsory Licensing
This case hinges on India’s patent laws and the provision for “compulsory licensing.” Compulsory licensing allows the government to authorize a generic manufacturer